Drug resistance

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
Monday, November 20, 2023
Select, CDI, Safety, Entrepreneurship, Fungal infection, WHO, AVP, Risk, Government, RN, WAAW, Sepsis, Patient, Infection, Antimalarial medication, Death, Drug resistance, Health, AMR, Invention, Acute kidney injury, Cancer, Diagnosis, Blood culture, Antimicrobial resistance, Hospital, Clostridioides difficile infection, Public, Education, Bloodstream infections, Pharmaceutical industry, Nursing

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Cancer therapy shows promise against tuberculosis

Retrieved on: 
Thursday, November 16, 2023
Texas Biomedical Research Institute, Apoptosis, Granuloma, Research, SAN, Immune system, Miliary tuberculosis, Protein, Macrophage, Mouse, Patient, Multimedia, Biomedicine & Pharmacotherapy, FDA, Death, Vaccine, Immunotherapy, Infection, Neoplasm, Drug resistance, Bacteria, Cancer, Human, Doctor of Philosophy, Growth, Volunteering, Cell, Tuberculosis, TB, Pharmaceutical industry, MD

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points: 
  • SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
  • - Larry Schlesinger, MD
    Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
  • The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
  • That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Retrieved on: 
Wednesday, November 15, 2023
Harvard University, Principal, Assistant, Research, Immune system, Gene, National Cancer Institute, Human Genome Sciences, Artificial intelligence, NCI, IGI, Patient, Genomics, The Department, Immunology, Radiation therapy, FACS, Master of Science, Icahn Genomics Institute, Neoplasm, Drug resistance, Stanford University, Escape Room, Principal investigator, Therapy, Mount Sinai Health System, University, Cancer, Survival, Doctor of Philosophy, Bangladesh Technical Education Board, Network, Metastasis, Danto Engineering Development Center, Drug development, Pharmaceutical industry, Management, Vaccine, Genetics, Columbia, Immunotherapy, MD, Health

NEW YORK, Nov. 15, 2023 /PRNewswire-PRWeb/ -- The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Key Points: 
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • "Cancer target discovery research has traditionally concentrated on pinpointing genes that facilitate cancer cell growth and survival.
  • It allows them to see how cancer genes affect not only cancer cells but also the immune system within tumors.

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Pandemic, Tuberculosis, SAN, DNA, Organization, Disease, WHO, Risk, Genomics, Molecular epidemiology, Data analysis, Whole genome sequencing, Illumina, Inc., Drug resistance, Clinical epidemiology, SARS-COV-2, Virus, GISAID, AIDS, Communication, Moeder, SARS-CoV-2, Face, Public, Influenza-like illness, Vaccine, Renewable energy, Malaria, Developing country, Illumina

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).
  • "We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina.
  • In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.
  • The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

November is Pancreatic Cancer Awareness Month

Retrieved on: 
Wednesday, November 8, 2023
FDA, Holiday, IND, John Engen, Legislation, Pancreatic tumor, EDV, ANDC, Disease, Cancer, Neoplasm, Rivian EDV, Survival rate, Pancreatic cancer, Safety, Oncology, PDAC, Drug resistance, Patient, Drug discovery, Investigational New Drug, Pharmaceutical industry, L.A

EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.

Key Points: 
  • EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.
  • The nanocell (designated EDVTM; EnGeneIC Dream Vector) is best described as an Antibody-Nanocell-Drug-Conjugate (ANDC) which also stimulates a powerful anti-tumour immune response.
  • Amazingly, after 15 months of EDV therapy, the patient’s cancer has disappeared and this has been achieved with minimal side effects.
  • In fact, the patient’s quality of life improved so much that she was allowed EDV-treatment breaks for holidays in Paris and Hawaii.

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023
Regulatory T cell, IRF1, Neoplasm, CCR8, FDA, Survival, PD-L1, HCC, NSCLC, Chemokine, Food, Renal cell carcinoma, Biomarker, ESCC, Head, PD-1, CHRS, Teff, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Cell, NPC, RCC, Interleukin, CD8, SITC, Poster, Nasopharyngeal carcinoma, Apoptosis, NK, Immunity, Immune system, Gene, Tumor microenvironment, Lung cancer, SHP2, Cancer, Hepatocellular carcinoma, GBP5, TME, Drug resistance, Patient, IL-27, Gene expression, Vaccine, Pharmaceutical industry, Office supplies, SHP1, HNSCC

REDWOOD CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.

Key Points: 
  • Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.
  • CCR8 is a chemokine receptor predominantly expressed by tumor infiltrating Tregs that suppress the body’s natural anti-cancer immune response.
  • Targeting CCR8 is a promising potential therapeutic strategy designed to deplete Tregs, reshape the tumor microenvironment and enhance anti-tumor immune response.
  • Data presented compare mechanistic data for LOQTORZI™ to commercially available anti-PD-1 monoclonal antibodies and demonstrate higher expression of key immune system biomarkers with LOQTORZI™.

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
TCE, Drug resistance, ROR1, Society, Hematology, CLL, Lymphoid neoplasms with plasmablastic differentiation, PK, Risk, Abstract, MCL, MRD, Trichloroethylene, Pharmacology, Autoregulation, CRS, Safety, AR, Manchester Grand Hyatt Hotel, Patient, Toxicity, Cerebral autoregulation, Mantle cell lymphoma, Therapeutic index, Birth control, Pharmaceutical industry

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.

Key Points: 
  • “We are pleased to announce our forthcoming oral presentation on the hematological arm of the NVG-111-01 Phase I clinical study (NCT04763083).
  • Building upon these achievements, we are advancing the development of NVG-111 into solid tumor indications,” said Professor Amit Nathwani, Founder and CEO of NovalGen.
  • This mitigates adverse events but also facilitates the administration of higher doses over extended durations, thereby expanding the therapeutic index.
  • NovalGen have shown that applying AR to TCEs does not affect the potency, but significantly reduces toxicity in pre-clinical models.

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Retrieved on: 
Thursday, November 2, 2023
Metabolomics, Cell cycle, Drug resistance, 65th Infantry Division (United States), Mantle cell lymphoma, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, MCL, G1 phase, Pharmacology, Differentiation, Cancer, Therapy, Patient, Pharmaceutical industry

NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023.

Key Points: 
  • The experiments included a broad comparison of narazaciclib with three other approved cyclin-D-kinase inhibitors (CDKis), used in combination with several BTKis,” said Steven Fruchtman, M.D., President and CEO of Onconova.
  • Dr. Fruchtman continued, “We were especially pleased by the broad translational data set that provided an understanding of narazaciclib’s role in cell cycle blockade.
  • These studies show that narazaciclib appears to act in the G1 phase of the cell cycle.
  • Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

Purple Biotech Fortifies NT219 Patent Protection

Retrieved on: 
Thursday, November 2, 2023
Patient, Patent, SCCHN, Head, China National Intellectual Property Administration, Maintenance, Cetuximab, Neoplasm, Tumor microenvironment, Drug resistance, Escape Room, Neck, Pharmaceutical industry

REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted a new patent for maintaining a pharmaceutical composition of NT219 in its active form.

Key Points: 
  • The new patent granted in China (# CN 115466205 B) expands Purple Biotech’s patent protection for NT219 in China.
  • The drug was previously issued patent in China that relates to the combinations of NT219 with various anti-cancer agents.
  • “Expanding patent protection for NT219’s composition is strategic for Purple Biotech and we believe that the grant of this new patent marks another step forward in our global intellectual property strategy.
  • China is a large and important market opportunity for us, and strengthening our patent coverage improves our competitive positioning in this territory,” stated Purple Biotech CEO, Gil Efron.

Vincerx Pharma To Present Three Posters at ASH 2023 in December

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, Therapy, University of Calgary, MDS, Drug resistance, Myelodysplastic syndrome, CD123, Activity, Novel, Safety, PALO, Humanized antibody, CDK9, PM, CXCR5, Drug, Society, ASH, Hematology, ADC, Lymphoid neoplasms with plasmablastic differentiation, MCL, University, Pharmacology, Cancer, Lymphoid leukemia, Cellular, Patient, Transplant, Model, Fine chemical, Medicinal plants, Flour

PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65th American Society for Hematology Meeting (ASH), taking place in San Diego California from December 9 to 12, 2023.

Key Points: 
  • "The three ASH 2023 posters highlight the strong scientific foundation for Vincerx’s programs.
  • “In addition, we are pleased to share preclinical data related to the activity of VIP924, a first-in-class CXCR5 ADC for the treatment of B-cell malignancies.
  • Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
    Presentation Time: 6:00 PM - 8:00 PM, Pacific Standard Time
    Title: Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib
    Session Name: 616.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
    Presentation Time: 6:00 PM - 8:00 PM, Pacific Standard Time